Robert Califf says there is a reason there is such a high turnover in the top post. He notes that the continuity and dedication of center directors is one of the reasons he returned.
US Food and Drug Administration Commissioner Robert Califf acknowledged that the challenges in heading up the agency make it difficult to attract people who are in the middle of their careers to the post.
During a 28 April Senate Appropriations Subcommittee hearing on the agency’s fiscal year 2023 budget request, ranking member Sen. John...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
